logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
Back
E

Edward L. Korn

national institutes of health (nih) - usa

64H-index
313Paper Count
1.7WCitation Count
Published Papers 44
Publication Date
logo
A note on rank-preserving structural failure time models to account for crossover
errClinical Trials
IF2.2
err2026-01-01
err0
PREAI
errTorres-Saavedra, Pedro A.; Freidlin, Boris; Jeong, Jong-Hyeon; Korn, Edward L.
errShare
errSave
Backfilling Patients in Phase I Dose Escalation Trials: Do it Safely and Efficiently
errEUROPEAN JOURNAL OF CANCER
IF7.1
err2024-10-01
err0
PREAI
errYuan, Y.; Korn, E.; Freidlin, B.
errShare
errSave
Backfilling Patients in Phase I Dose-Escalation Trials Using Bayesian Optimal Interval Design (BOIN)
errCLINICAL CANCER RESEARCH
IF10.2
err2023-12-04
err4
PREAI
errZhao, Yixuan; Yuan, Ying; Korn, Edward L.; Freidlin, Boris
errShare
errSave
The potential to backfill in phase I trials: the National Cancer Institute's Cancer Therapy Evaluation Program experience
errJNCI CANCER SPECTRUM
IF4.1
err2023-11-24
err1
errOAAI
errFoster, Jared C.; Korn, Edward L.; Freidlin, Boris; Moscow, Jeffrey A.
errShare
errSave
Dose optimization during drug development: whether and when to optimize
errJNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
IF7.2
err2022-12-19
err13
errOAAI
errKorn, Edward L.; Moscow, Jeffrey A.; Freidlin, Boris
errShare
errSave
Augmenting randomized clinical trial data with historical control data: Precision medicine applications
errJNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
IF7.2
err2022-09-26
err9
errOAAI
errFreidlin, Boris; Korn, Edward L.
errShare
errSave
Clinical Benefit Scales and Trial Design: Some Statistical Issues
errJNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
IF7.2
err2022-05-18
err2
errOAAI
errKorn, Edward L.; Allegra, Carmen J.; Freidlin, Boris
errShare
errSave
A Problematic Biomarker Trial Design
errJNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
IF7.2
err2021-07-21
err8
errOAAI
errFreidlin, Boris; Korn, Edward L.
errShare
errSave
Platform Trials - Beware the Noncomparable Control Group
errNEW ENGLAND JOURNAL OF MEDICINE
IF78.5
err2021-04-22
err50
errOAAI
errDodd, Lori E.; Freidlin, Boris; Korn, Edward L.
errShare
errSave
Evaluation of the contribution of randomised cancer clinical trials evaluating agents without documented single-agent activity
errESMO OPEN
IF8.3
err2020-01-01
err4
errOAAI
errFoster, Jared; Freidlin, Boris; Korn, E. L.; Smith, Malcolm
errShare
errSave
Moving Molecular Profiling to Routine Clinical Practice: A Way Forward?
errJNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
IF7.2
err2019-12-23
err4
errOAAI
errFreidlin, Boris; Allegra, Carmen J.; Korn, Edward L.
errShare
errSave
Single-Arm Phase II Trials of Combination Therapies: A Review of the CTEP Experience 2008-2017
errJNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
IF7.2
err2019-09-23
err8
errOAAI
errFoster, Jared C.; Freidlin, Boris; Kunos, Charles A.; Korn, Edward L.
errShare
errSave
Interim monitoring for non-inferiority trials: minimizing patient exposure to inferior therapies
errANNALS OF ONCOLOGY
IF65.4
err2018-03-01
err8
errOAAI
errKorn, E. L.; Freidlin, B.
errShare
errSave
Two-by-Two Factorial Cancer Treatment Trials: Is Sufficient Attention Being Paid to Possible Interactions?
errJNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
IF7.2
err2017-08-08
err13
errOAAI
errFreidlin, Boris; Korn, Edward L.
errShare
errSave
Assessing treatment efficacy in the subset of responders in a randomized clinical trial
errANNALS OF ONCOLOGY
IF65.4
err2017-07-01
err7
errOAAI
errKorn, E. L.; Othus, M.; Chen, T.; Freidlin, B.
errShare
errSave
Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements
errJNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
IF7.2
err2017-03-17
err57
errOAAI
errKorn, Edward L.; Freidlin, Boris
errShare
errSave
A retrospective study of Class II mixed-dentition treatment
errANGLE ORTHODONTIST
IF3.2
err2016-07-08
err7
errOAAI
errOh, Heesoo; Baumrind, Sheldon; Korn, Edward L.; Dugoni, Steven; Boero, Roger; Aubert, Maryse; Boyd, Robert
errShare
errSave
RE: Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-Analysis of Clinical Trials Leading to FDA Approval
errJNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
IF7.2
err2016-02-24
err1
errOAAI
errFreidlin, Boris; Korn, Edward L.
errShare
errSave
Statistical controversies in clinical research: assessing pathologic complete response as a trial-level surrogate end point for early-stage breast cancer
errANNALS OF ONCOLOGY
IF65.4
err2016-01-01
err43
errOAAI
errKorn, E. L.; Sachs, M. C.; McShane, L. M.
errShare
errSave
Design Issues in Randomized Clinical Trials of Maintenance Therapies
errJNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
IF7.2
err2015-08-18
err16
errOAAI
errFreidlin, Boris; Little, Richard F.; Korn, Edward L.
errShare
errSave

Research Directions

No research directions
Co-authors
Cooperation Journals
G
Gabriel N. Hortobágyi
H-index: 187 · Papers: 1.9K
A
Adrian L. Harris
H-index: 187 · Papers: 2.1K
R
Richard Pazdur
H-index: 134 · Papers: 1.0K
S
Steven M. Larson
H-index: 133 · Papers: 1.2K
C
Christos Sotiriou
H-index: 122 · Papers: 1.1K
View more